# OnCo record paper-combi-d-long-lancet-2015 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-combi-d-long-lancet-2015/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-combi-d-long-lancet-2015" ;
  schema:name "COMBI-d: dabrafenib and trametinib versus dabrafenib alone for BRAF V600-mutant melanoma"@en ;
  schema:description "Adding the MEK inhibitor trametinib to the BRAF inhibitor dabrafenib lengthened survival and reduced the skin cancers caused by BRAF inhibition alone in metastatic BRAF-mutant melanoma, establishing dual blockade as the standard for targeted therapy."@en ;
  schema:url <https://onco.cc/key-papers/paper-combi-d-long-lancet-2015/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S0140-6736(15)60898-4>, <https://pubmed.ncbi.nlm.nih.gov/26037941/> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(15)60898-4> ;
  schema:datePublished "2015"^^xsd:gYear ;
  schema:author "Long GV, Stroyakovskiy D, Gogas H, et al." ;
  onco:cancers <https://onco.cc/cancers/braf-v600-melanoma/> ;
  onco:drugs <https://onco.cc/drugs/dabrafenib/>, <https://onco.cc/drugs/trametinib/> ;
  onco:trials <https://onco.cc/trials/combi-d/> ;
  onco:journals <https://onco.cc/journals/lancet/> .